Protagonist Therapeutics (PTGX) Competitors $55.15 +1.41 (+2.62%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$54.98 -0.17 (-0.32%) As of 07/25/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. MRNA, RDY, QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, and LEGNShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Moderna (MRNA), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Moderna Dr. Reddy's Laboratories QIAGEN Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Protagonist Therapeutics (NASDAQ:PTGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate PTGX or MRNA? Protagonist Therapeutics presently has a consensus price target of $66.10, suggesting a potential upside of 19.85%. Moderna has a consensus price target of $46.11, suggesting a potential upside of 35.03%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Do institutionals and insiders have more ownership in PTGX or MRNA? 98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is PTGX or MRNA more profitable? Protagonist Therapeutics has a net margin of 27.04% compared to Moderna's net margin of -105.67%. Protagonist Therapeutics' return on equity of 9.22% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics27.04% 9.22% 8.31% Moderna -105.67%-28.69%-21.94% Which has more volatility & risk, PTGX or MRNA? Protagonist Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Which has stronger valuation and earnings, PTGX or MRNA? Protagonist Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M7.87$275.19M$0.7573.53Moderna$3.14B4.21-$3.56B-$8.73-3.91 Does the media favor PTGX or MRNA? In the previous week, Protagonist Therapeutics had 1 more articles in the media than Moderna. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 13 mentions for Moderna. Protagonist Therapeutics' average media sentiment score of 0.81 beat Moderna's score of 0.71 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryProtagonist Therapeutics beats Moderna on 13 of the 16 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.33B$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio73.5321.1828.1020.05Price / Sales7.87288.50432.4490.07Price / Cash11.9042.7636.2258.56Price / Book4.878.378.665.87Net Income$275.19M-$55.19M$3.25B$258.55M7 Day Performance-0.59%5.88%4.23%3.74%1 Month Performance-0.13%17.33%10.52%11.75%1 Year Performance36.92%4.42%34.41%18.03% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics1.3845 of 5 stars$55.15+2.6%$66.10+19.9%+32.7%$3.33B$434.43M73.53120News CoverageInsider TradeMRNAModerna4.2995 of 5 stars$30.97-0.9%$46.61+50.5%-71.6%$12.09B$3.24B-3.555,800Upcoming EarningsAnalyst ForecastRDYDr. Reddy's Laboratories2.7434 of 5 stars$14.57+0.6%$16.95+16.4%-9.3%$12.09B$3.81B21.9427,811Earnings ReportQGENQIAGEN3.5861 of 5 stars$48.06-0.6%$49.40+2.8%+26.1%$10.75B$1.98B120.495,765Analyst DowngradeAnalyst RevisionVTRSViatris2.4337 of 5 stars$8.90+0.2%$10.40+16.9%-20.0%$10.42B$14.74B-2.8132,000ASNDAscendis Pharma A/S3.4327 of 5 stars$168.02-1.1%$223.07+32.8%+24.6%$10.39B$393.54M-26.751,017Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.8206 of 5 stars$104.90flat$109.00+3.9%+375.4%$8.93B$42.28M-52.4530Positive NewsBBIOBridgeBio Pharma4.6357 of 5 stars$45.90-1.3%$61.50+34.0%+73.4%$8.83B$221.90M-13.00400Analyst DowngradeBPMCBlueprint Medicines1.0836 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Positive NewsUpcoming EarningsROIVRoivant Sciences2.5987 of 5 stars$11.48+0.3%$16.50+43.7%+7.5%$7.78B$29.05M-45.92860News CoveragePositive NewsInsider TradeLEGNLegend Biotech3.7084 of 5 stars$42.23+1.5%$73.33+73.7%-26.7%$7.64B$627.24M-71.582,609Positive News Related Companies and Tools Related Companies Moderna Alternatives Dr. Reddy's Laboratories Alternatives QIAGEN Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts